Clinical trial
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia…
NCT02467270 · Takeda, Industry · Completed
Key facts
| NCT number | NCT02467270 |
|---|---|
| Title | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses |
| Official title | A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses |
| Acronym | OPTIC |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia, Chronic, Chronic Phase |
| Intervention type | Drug |
| Interventions | Ponatinib |
| Enrollment | 283 |
| Start date | Jun 30, 2015 |
| Primary completion | Apr 14, 2020 |
| Completion | Apr 23, 2025 |
| First posted | Jun 10, 2015 |
| Last update posted | May 1, 2025 |
| Countries | Argentina, Australia, Canada, Chile, Czechia, Denmark, France, Germany, Hong Kong, Italy, Poland, Portugal and 9 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: